Whole tissue cervical mapping of HPV infection: Molecular evidence for focal latent HPV infection in humans

Anne Hammera,b,⁎, Maurits NC de Koningc, Jan Blaakaerd, Torben Steinicheb,e, John Doorbarf, Heather Griffin,f, Else Mejgaard, Hans Svanholmg, Wim GV Quintc, Patti E. Gravitt

a Department of Obstetrics and Gynecology, Aarhus University Hospital, Denmark
b Department of Clinical Medicine, Aarhus University, Denmark
c DDL Diagnostic Laboratory, Rijswijk, the Netherlands
d Department of Obstetrics and Gynecology, Odense University Hospital, Denmark
e Department of Pathology, Aarhus University Hospital, Denmark
f Department of Pathology, University of Cambridge, United Kingdom
g Department of Pathology, Randers Hospital, Denmark
h Department of Global Health, Milken Institute School of Public Health, the George Washington University, USA

ARTICLE INFO

Keywords:
HPV
Papillomavirus
Humans
Virus latency
Uterine cervical neoplasm
Molecular biology

ABSTRACT

In this study, we aimed to provide molecular evidence of HPV latency in humans and discuss potential challenges of conducting studies on latency. We analyzed the entire cervix of two women who underwent hysterectomy unrelated to cervical abnormality. The cervices were sectioned into 242 and 186 sets respectively, and each set was tested separately for HPV using the SPF10-PCR-DEIA-LiPA25 system. To identify whether there was any evidence of transforming or productive infection, we used the biomarkers E4 and P16INK4a to stain slides immediately adjacent to HPV-positive sections. HPV was detected in both cervices. In patient 1, 1/242 sets was positive for HPV31. In patient 2, 13/186 sets were positive for HPV18 and 1/186 was positive for HPV53. The infection was very focal in both patients, and there was no sign of a transforming or productive infection, as evaluated by the markers E4 and P16INK4a. Had we only analyzed one set from each block, the probability of detecting the infection would have been 32.3% and 2%, respectively. Our findings support the idea that HPV may be able to establish latency in the human cervix; however, the risk associated with a latent HPV infection remains unclear.

1. Introduction

For several years, there has been discussion as to whether or not human papillomavirus (HPV) is able to establish latency in the epithelium of the human uterine cervix [1–4], with the possibility of viral reactivation during periods of immune deficiency [5]. Despite evidence from clinical studies, such as the reporting of HPV re-appearance following an HPV-negative test result [6–9] in sexually abstinent women and a higher risk of HPV-related disease in immune suppressed individuals, including organ transplant recipients [10] and HIV seropositive patients [11,12], there is still no consensus in the scientific community on whether or not HPV is able to establish latency. If HPV is able to establish latency in humans, the viral genome would be expected to be maintained in the basal epithelial cell layer of stratified epithelium, with no shedding of viral particles and without clinical evidence of disease, similar to what has been reported in the animal model [3,5]. Moreover, the infection may be focal, and be characterized by low HPV DNA copy number and possibly also a low number of infected cells [13]. These characteristics provide a challenge for the detection of a latent HPV infection, and may explain why a latent HPV infection is not picked up by routine HPV testing of cervical cytology samples. In cervical cytology samples, only the superficial cell layer is sampled for HPV testing. The detection of a latent HPV infection is likely to be facilitated by the use of samples that include the basal epithelial cell layer, such as tissue sections from the cervix. Furthermore, an intensive sampling procedure may be required in human studies to ensure detection, as there is no tattoo ink to guide us to the site of previous infection, unlike in the animal model [3]. In the present

Abbreviations: HPV, (human papilloma virus); HIV, (human immunodeficiency virus); DNA, (deoxyribonucleic acid); mRNA, (messenger ribonucleic acid); HE, (hematoxylin and eosin)

⁎ Correspondence to: Department of Obstetrics and Gynecology, Aarhus University Hospital / Department of Clinical Medicine, Aarhus University, Palle Juul Jensens Boulevard 99, DK-8200 Aarhus N, Denmark.
E-mail address: ahlaursden@clin.au.dk (A. Hammer).

https://doi.org/10.1016/j.pvr.2019.02.004
Received 6 December 2018; Received in revised form 1 February 2019; Accepted 13 February 2019
Available online 14 February 2019
2405-8521/ © 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
analyses were performed using the SPF10-PCR-DEIA-LiPA25 system and the MagNA Pure LC instrument as described elsewhere [15]. HPV DNA was isolated from 200μL Surepath suspension (Becton Dickinson and Company, Franklin, NJ, USA) containing exfoliated cervical cells, using the MagNA Pure LC instrument, as described previously [14]. For surgical removal, both patients had a normal cervical cytology and were HPV-negative on routine testing using COBAS 4800 (Roche Molecular Diagnostics). After surgical removal, an experienced gynecological pathologist reviewed hematoxylin and eosin (H&E) stained cervical tissue slides by routine bright field microscopy and found no evidence of HPV infection, cervical neoplasia, or other disease.

Fig. 1 illustrates the processing of cervical samples. After surgical removal, the cervix was separated from the uterine corpus (a) and sliced open in the anterior wall. The cervix was fixed to a styrofoam plate covered with a sterile glove (b) and subsequently fixed with formalin for approximately 24 h. The following day, the cervix was cut into 3-mm sections (c) and embedded in paraffin. To avoid cross-contamination, we used sterile utensils only (i.e., gloves, syringes, scalpels, etc.).

After the procedure described in Fig. 1, the entire cervix was sectioned in both patients, as illustrated in Fig. 2, resulting in up to 30 sets per formalin fixed, paraffin embedded block; a set consists of one section of 24 sets per formalin fixed, paraffin embedded block; a set consists of one section of 4 μm for H&E, 3 sections of 8 μm for whole tissue SPF10 PCR, and four unstained sections of 4 μm for further analyses. To check for changes characteristic of viral infection, H&E slides adjacent to HPV-positive slides were examined by a pathologist experienced in routine diagnostic gynecological pathology at DDL diagnostic Laboratory.

DNA extraction of tissue samples was performed using a proteinase K procedure as described previously [14]. For cytological samples, DNA was isolated from 200 μL Surepath suspension (Becton Dickinson and company, Franklin, NJ, USA), containing exfoliated cervical cells, using the MagNA Pure LC instrument as described elsewhere [15]. HPV analyses were performed using the SPF10-PCR-DEIA-LiPA25 system (SPF10 HPV LiPA25 version 1; Labo Bio-Medical products, Rijswijk, The Netherlands) as described previously [16,17]. The DEIA is an ELISA-based assay that allows detection of at least 69 HPV types, whereas the LiPA25 allows qualitative identification of the following 25 HPV genotypes: 6, 11, 16, 18, 31, 33, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 66, 68/73, 70, and 74.

During the testing, extensive measures were taken to avoid cross-contamination. Thus, controls were incorporated in all phases of the testing and all controls were tested in the DEIA. 1) The sectioning included the cutting of an empty paraffin block at the beginning and at the end of each block, and after every 10 sets (Fig. 2). 2) Each DNA extraction run included two negative controls and one positive control. 3) The PCR included a negative and a positive control. 4) The DEIA included a negative, a borderline (to establish the cut-off for positivity), and a positive control. 5) The LiPA25 contained a positive control, which was the PCR positive control. Amplification failure or contamination was not observed. All HPV analyses were performed at DDL Diagnostic Laboratory, the Netherlands.

2.1. P16 immunohistochemistry and E4 immunofluorescence

Sections adjacent to HPV-positive slides were subject to further analysis with the purpose of localizing the infection and explore potential evidence of an HPV infection. P16INK4a staining was performed on the first adjacent slide in each HPV-positive set as this marker is commonly used as a biomarker of transforming HPV infections. The p16INK4a staining was performed using the CINtec system as described elsewhere [18]. For the present study we used p16INK4a positive tissue as internal control. Each slide contained the study tissue section as well as a section from a CIN3 (cervical intraepithelial neoplasia grade 3 or worse) lesion known to be p16INK4a positive.

Furthermore, we used a recently developed pan HPV E4 antibody (SiIL grade-E4-1 kit containing XR-E4-1 monoclonal antibody, Labo Bio-Medical Products, Rijswijk, The Netherlands) able to detect the E4 proteins of at least 15 types of high-risk HPV (including HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 67, and 70) [18] on the second adjacent slide. The HPV E4 protein is expressed in infected squamous cells that have initiated the productive stage of the viral life cycle [19-21], which occurs primarily in low-grade disease [22]. The E4 marker can be detected using conventional immunohistochemistry or immunofluorescence approaches [18], but in this study we used an immunofluorescence as outlined in previous studies [22,23]. Briefly, the sections adjacent to HPV-positive sets were deparaffinized in xylene, and rehydrated in a descending alcohol series. For epitope retrieval, slides were autoclaved in solution D, pH 6.0 (Dako, Glostrup, Denmark) at 121 °C for 2 min. The antibodies against
E4 (panHPVE4) were applied 1:100 and incubated over night at 4 °C. Visualization was performed with 150-fold diluted Alexa-488 (green) conjugated anti-mouse secondary antibody against E4 (Invitrogen, Paisley, UK). Finally, a nuclear counterstaining was performed using DAPI (blue) (Sigma, St. Louis, MO, USA). A CIN1 known to be caused by HPV16 was used as a positive control and gave the characteristic pattern of E4 staining as described previously [20,22]. P16INK4a staining was performed at DDL, Diagnostic Laboratory, The Netherlands, whereas the panHPVE4 staining was performed at the Department of Pathology, University of Cambridge, UK.

We defined possible viral latency as follows: HPV detected in the tissue with no evidence of E4 and p16INK4a positivity, no clinical or histo-pathological evidence of disease, no cytological abnormality, and HPV-negative on liquid based cytology.

2.2. Statistical analysis

We used our results of the density of latent HPV detection to estimate the probability that a given cervix would yield an HPV-positive result if only a sample of tissue was tested from each specimen block. Assuming the results follow a binomial distribution, we calculated the probability of detecting HPV in a given cervix as follows:

\[
P(x \geq 1) = 1 - (1-p)^n
\]

where \( P(x \geq 1) \) = probability that at least one sampled set tests positive, \( n \) = number of sets tested, and \( p \) = probability that a set contained a latent HPV infection based on the results of our study.

The Danish Ethics Committee (1-10-72-432-12) and the Danish Data Protection Agency (1-16-02-211-12) approved the study. Both patients signed an informed consent form prior to enrollment.

3. Results

Both patients selected for the present study had a total laparoscopic hysterectomy; patient 1 due to a bleeding disorder and patient 2 because of predisposition to ovarian cancer. Patient 1 was 52 years old and premenopausal at the time of surgery, whereas patient 2 was 67 years old and postmenopausal. Patient 1 had 12 lifetime sex partners and was in 1988 diagnosed with HSIL, for which she did not receive surgical treatment. Patient 2 was diagnosed with ASC-H in 2010, which could not be verified histologically, and she had 23 sex partners during her life. Both patients reported no current or previous use of hormone replacement therapy (Table 1). Additionally, both patients had no record of histologically verified cervical abnormality within 5 years of hysterectomy.

HPV was detected in both patients when the entire cervix was evaluated with the use of whole tissue PCR. In patient 1, a total of 9 blocks were sectioned into 186 sets. Seven of the nine blocks contained HPV-positive sets. HPV-positive sets were mainly adjacent to HPV-positive sets (Fig. 3). Of 186 sets tested, 13 sets (7.0%) were HPV18 positive and one set (0.5%) was positive for HPV53. In patient 2, a total of 11 blocks were sectioned into 242 sets of which one set (0.4%) was positive for HPV31, and one set was borderline positive on the DEIA. However, because the borderline positive sample was negative by reverse hybridization using the LiPA25 strip, the sample was deemed HPV negative, according to standard protocol.

Fig. 3 illustrates the distribution of HPV infection across the cervix. The HPV infection was very focal in both cervices, but as a result of more HPV-positive sets in patient 1, the infection appeared more widespread in patient 1 compared to patient 2.

Table 1

| Characteristics                  | Patient 1 | Patient 2 |
|----------------------------------|-----------|-----------|
| Age (years)                      | 52        | 67        |
| Previous abnormal cervical cytolgy | HSIL in 1988, not surgically treated | ASC-H in 2010, normal histology |
| Number of life-time sex partners | 12        | 23        |
| Number of new sex partners by age (years) | Age 13–19: 3 Age 20–29: 8 Age 30–39: 1 Age 40–49: 0 Age 50–59: 0 | Age 13–19: 4 Age 20–29: 11 Age 30–39: 3 Age 40–49: 3 Age 50–59: 1 Age 60–69: 2 |
| Number of blocks tested          | 9         | 11        |
| Amount of tissue tested by SPF10-PCR (μm) | 4464 | 5808 |
| Number of SPF10-PCR tests per formed        | 186        | 242        |

We carefully reviewed H&E-stained slides adjacent to HPV-positive sections and found no evidence of a productive HPV infection by bright field microscopy; i.e., no micro lesions, koilocytosis, dyskariotic cells, etc. As cervical smears obtained prior to surgery were initially tested using COBAS 4800, which has lower sensitivity, we re-tested the two cervical cytology samples obtained prior to surgery using the SPF10-PCR-DEIA-LiPA25 system, and both samples were HPV-negative.

To explore if HPV DNA positivity may be associated with a productive viral infection, we tested adjacent slides to HPV-positive sets for the presence of E4. While the positive controls stained strongly, all adjacent slides to HPV-positive set were negative for E4.

Overexpression of the cellular biomarker p16INK4a in cervical tissue is usually associated with the presence of the viral oncoproteins, E6 and E7. All adjacent slides to HPV-positive sets were negative for p16INK4a, while all positive and negative controls did not suggest a failure in the analysis. The absence of E4 and p16INK4a may therefore suggest that the HPV infection detected represents a non-transforming and non-productive infection, such as a latent HPV infection.

Acknowledging that the methodology applied in the present study was very costly and time consuming and not feasible for use in future...
studies, we used the results above to calculate the probability of detecting HPV in a cervix if only a proportion of the total tissue is sampled for PCR testing. Table 2 summarizes the probability of a cervix testing HPV-positive by a range of proportion of HPV-positive sets (rows) and proportion of the cervix analyzed (columns). In the present study, we found 7.5% of sets were HPV-positive in patient 1. Thus, the probability of an HPV-positive test result would be 32.3% had we only analyzed one set from each block. In patient 2, 0.4% of sets were HPV-positive, which equals to a 2% probability of an HPV-positive result if we only analyzed one set from each block.

4. Discussion

Thus far, several clinical and epidemiological studies have suggested that HPV is likely being controlled by the immune system rather than cleared [1, 4, 24–26]. Such studies include the periodical shedding of viral particles [27], the re-appearance of HPV following an HPV-negative test [8], and the increase in HPV prevalence after the initiation of immune suppression [25]. Although animal studies have shown that papillomavirus DNA can be detected in a latent stage up to one year after lesion regression, studies reporting molecular evidence of HPV latency in the human uterine cervix are still lacking.

In the present study, HPV was detected in the human uterine cervix in both patients, with no evidence of a productive or transforming infection by immunohistochemistry and immunofluorescence, and without clinical, cytological, or histopathological evidence of HPV-related disease. These findings may represent HPV infections below detectable levels or possibly molecular evidence of HPV latency. Our results are consistent with previous animal studies in which papillomavirus DNA and mRNA expression was detected in the mucosa following an incident infection without there being evidence of clinical disease [3, 28]. It is unlikely that infections in this latent state pose any immediate risk of severe disease as evidence by the lack of abnormal pathology; however, it remains unclear whether future reactivation from the latent state would result in disease risk similar to that observed in young women with newly acquired infection.

In the animal models, tattoo ink is often used at the site of inoculation, which allows for the distinctive analyses of tissue known to have been exposed to the virus [3, 5, 28]. In the human uterine cervix no such marker exists. Additionally, results from the animal model suggest that, during HPV latency, only a few basal epithelial cells may harbor HPV DNA and at a very low copy number. These factors provide a challenge for the detection of a latent HPV infection and highlight the importance of using a highly sensitive HPV assay and an extensive sampling procedure. In the animal model, viral latency was only detected using a PCR-based technique as the viral copy number during latency was too low to allow for visual detection by in situ hybridization [3] using techniques available at the time of the study.

Due to the focal nature of a latent HPV infection as reported in the animal model, we chose to perform an intensive sampling and testing procedure on two patients who were considered at high risk of harboring a latent HPV infection (i.e., ≥ 10 lifetime sex partners and a previous record of HPV related disease). This decision was based on previous studies reporting that HPV detection at older age is more likely attributed to previous and not recent sexual activity [9, 29, 30]. The focal nature of the HPV infections observed in the present study suggests that the infection may have been missed had we only analyzed one section from each block. As reported in Table 2, an intense sampling and testing procedure will be required to accurately determine the presence or absence of a latent HPV infection.

To the best of our knowledge, only a few studies have reported evidence of possible HPV latency in humans. Two studies analyzed normal, HPV-positive cervical tissue with no signs of viral replication, adjacent to a cervical lesion (i.e., cervical intraepithelial neoplasia or cancer) [31, 32], whereas another study analyzed morphologically normal cervixes. In the study by Leonard et al., the authors reported the presence of HPV in 42% of morphologically normal cervixes using in situ hybridization and PCR-based methods [33]. Because persistence of HPV in the absence of clinical disease does not preclude viral activities acquired for genome maintenance, such as replication of the viral genome below detectable levels or production of viral transcripts, p16 and E4 is often used as markers of a productive infection. However, although the authors reported the absence of p16 and E4 like in the present study, it is unclear if the findings reported by Leonard et al. reflect “true” latency as cervical cytology samples were not analyzed for the presence of HPV. Thus, it is unclear if the high HPV prevalence

Table 2

| Percentage of sets tested | 5 | 10 | 15 | 20 | 25 |
|---------------------------|---|----|----|----|----|
| Assumed percentage of HPV-positive sets | 0.1 | 0.5 | 1.0 | 1.5 | 2.0 | 2.5 |
|                           | 0.5 | 2.5 | 4.9 | 7.2 | 9.5 | 11.8 |
|                           | 1.0 | 4.9 | 9.6 | 14.0 | 18.2 | 22.2 |
|                           | 2.0 | 9.6 | 18.3 | 26.1 | 33.2 | 39.7 |
|                           | 5.0 | 22.6 | 40.1 | 53.7 | 64.2 | 72.3 |
|                           | 7.5 | 32.3 | 54.1 | 68.9 | 79.0 | 85.8 |
|                           | 10.0 | 41.0 | 65.1 | 79.4 | 87.8 | 92.8 |

Fig. 3. Distribution of HPV in the human uterine cervix. Each pie chart illustrates the cervix seen from the vagina and the location of the HPV-positive test results. The central white circle illustrates the cervical orifice (i.e. opening to the uterine cavity). Each large pie piece represents a 3-mm block and each smaller slice represents a whole tissue section set tested by SPF15 PCR.
reported in their study may be a result of an active HPV infection (that would have been picked up by routine HPV testing of a cervical cytology sample), rather than a latent HPV infection, or a combination. In our study, both patients were HPV-negative and had normal cytology on a liquid based cytology sample obtained prior to surgery. Additionally, we found no evidence of E4 and p16 on slides adjacent to HPV-positive sections, which suggest that the infection is non-productive and might represent a latent HPV infection. Unfortunately, we are unable to determine if the HPV detected represents a new infection in its early stage, a regressing infection, or a “true” latent infection, as there is currently no molecular marker available that is able to distinguish between these stages. We cannot exclude that the HPV infection in patient 2 may represent an early infection because of recent new sex partners; however, we find a new early infection unlikely in patient 1, as there was no reporting of new sex partners within the preceding 10–15 years.

4.1. Strengths and limitations

Our data demonstrates that studies attempting to use hysterectomy samples to estimate a woman-level prevalence of latent HPV must use a very sensitive PCR-based HPV assay with intensive sampling across the tissue due to the focal nature of the infections. Sampling of even 25% of very sensitive PCR-based HPV assay with intensive sampling across the partners; however, we find an early infection unlikely in patient 1, distinguish between these stages. We cannot exclude that the HPV infection in patient 2 may represent an early infection because of recent new sex partners; however, we find a new early infection unlikely in patient 1, as there was no reporting of new sex partners within the preceding 10–15 years.

Conflict of interest

The authors report no conflicts of interest.

References

[1] P.E. Gravett, Gravity and impact of human papillomavirus latency, Open Virol. J. 6 (2012) 198–203, https://doi.org/10.2174/1874357912006010198.
[2] J. Doorbar, Molecular biology of human papillomavirus infection and cervical cancer, Clin. Sci. 110 (2006) 525–541, https://doi.org/10.1042/CS20050569.
[3] G.A. Maglennon, P. McIntosh, J. Doorbar, Persistence of viral DNA in the epithelial basal layer suggests a model for papillomavirus latency following immune regression, Virology 414 (2011) 153–163, https://doi.org/10.1016/j.virol.2011.03.019.
[4] P.E. Gravett, R.L. Winer, Natural history of HPV infection across the lifespan: role of viral latency, Viruses 9 (2017), https://doi.org/10.3390/v9100067.
[5] G.A. Maglennon, P.B. McIntosh, J. Doorbar, Immunosuppression facilitates the re-activation of latent papillomavirus infections, J. Virol. 88 (2014) 710–716, https://doi.org/10.1128/JVI.02589-13.
[6] R.P. Insaing, G. Perez, C.M. Wheeler, L.A. Koutsy, S.M. Garland, S. Lesoldier, E.A. Joura, D.G. Ferris, M. Steben, D.R. Brown, E.H. Elbash, J. Paavonen, R.M. Haupt, FUTUREI investigators, incidence, duration, and reappearance of type-specific cervical human papillomavirus infections in young women, Cancer Epidemiol. Biomark. Prev. 19 (2010) 1585–1594, https://doi.org/10.1158/1055-9966.EPI-09-1235.
[7] K.A. Brogaard, C. Munk, T. Ihlem, K. Frederiksen, S.K. Kjaer, Detection of oncogenic human papillomavirus (HPV) among HPV-negative older and young women after 7 years of follow-up, J. Med. Virol. 86 (2014) 975–982, https://doi.org/10.1002/jmv.23914.
[8] N.J. Solomon, W.J. Veldhuijzen, D.A.M. Heideman, P.J.F. Snijders, C.J.L.M. Meijer, J. Bechthol, HPV-positive women with normal cytology remain at increased risk of CIN3 after a negative repeat HPV test, Br. J. Cancer (2017), https://doi.org/10.1038/bjc.2017.309.
[9] A.F. Rostiych, A.E. Burke, R.P. Viscidi, M.I. Silver, K. Chang, P.E. Gravett, Contributions of recent and past sexual partnerships on incident human papillomavirus detection: acquisition and reactivation in older women, Cancer Res. 72 (2012) 6183–6190, https://doi.org/10.1158/0008-5472.CAN-12-2635.
[10] M.M. Madeleine, J.L. Finch, G.F. Lynch, M.T. Goodman, E.A. Engels, HPV-related cancers after solid organ transplantation in the United States, Am. J. Transplant. 13 (2013) 3202–3209, https://doi.org/10.1111/ajt.12472.
[11] I. Heard, J.M. Taviss, V. Schmitz, L. Mandelbrot, M.D. Katzchikine, G. Orth, Increased risk of cervical disease among human immunodeficiency virus-infected women with severe immunosuppression and high human papillomavirus load(1), Obstet. Gynecol. 96 (2000) 403–409.
[12] L.J. Menezes, S. Puongalali, M. Tommasiho, H.Y. Lin, N. Kumaramany, K.J. Fisher, S. Saravanan, T. Ghei, C. Ezhilarasi, A. Jeeva, B. Lu, A.R. Giuliano, Prevalence and concordance of human papillomavirus infection at multiple anatomic sites among HIV-infected women from Chennai, India, Int. J. STD Aids. 27 (2016) 543–553, https://doi.org/10.1177/0956462415687266.
[13] G.A. Maglennon, J. Doorbar, The biology of papillomavirus latency, Open Virol. J. 6 (2012) 190–197, https://doi.org/10.2174/1874357912006010190.
[14] W.G. Quint, G. Scholte, L.J. van Doorn, B. Kleter, P.H. Smits, J. Doorbar, Comparative analysis of human papillomavirus infections in cervical scrapes and biopsy specimens by general SPF(10) PCR and HPV genotyping, J. Pathol. 194 (2001) 51–58.
[15] L.J. van Doorn, A. Molijn, B. Kleter, W. Quint, B. Colau, Highly effective detection of human papillomavirus 16 and 18 DNA by a testing algorithm combining broad-spectrum and type-specific PCR, J. Clin. Microbiol. 44 (2006) 3292–3298, https://doi.org/10.1128/JCM.00539-06.
[16] B. Kleter, L.J. van Doorn, L. Schrauwen, A. Molijn, S. Sastrowijoto, J. ter Schegget, J. Lindeman, B. ter Harmel, M. Burger, W. Quint, Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus, J. Clin. Microbiol. 37 (1999) 2508–2517.
[17] B. Kleter, L.J. van Doorn, J. ter Schegget, L. Schrauwen, K. van Krimpen, M. Burger, B. ter Harmel, W. Quint, Novel short-fragment PCR assay for highly sensitive broad-spectrum detection of anogenital human papillomavirus, Am. J. Pathol. 153 (1998) 1731–1739, https://doi.org/10.1016/S0002-9440(10)65688-X.
[18] P. van Baars, H. Griffin, Z. Wu, Y.J. Soneji, M. van der Sandt, R. Arora, J. van der Marel, B. ter Harmel, R. Jach, K. Okon, H. Huras, D. Jenkins, W. Quint, J. Doorbar, Investigating diagnostic problems of CIN1 and CIN2 associated with high-risk HPV by combining the novel molecular biomarker PanHPV4 with P16INKa, Am. J. Surg. Pathol. 39 (2015) 1518–1528, https://doi.org/10.1097/PAS.0000000000000498.
[19] K. Middleton, W. Peh, S. Southern, H. Griffin, K. Sollar, T. Nakahara, A. El-Shifer, L. Morris, R. Seth, M. Hibma, D. Jenkins, P. Lambert, N. Coleman, J. Doorbar, Organizational human papillomavirus productive cycle during neoplastic progression provides a basis for selection of diagnostic markers, J. Virol. 77 (2003) 10186–10201.
[20] J. Doorbar, The E4 protein: structure, function and patterns of expression, Virology 445 (2013) 80–98, https://doi.org/10.1016/j.virol.2013.06.015.
[21] C. Borgogna, E. Zavattaro, M. De Andrea, H. Griffin, V. Dell’Oste, B. Azimonti, M.M. Landini, W.L. Peh, H. Pfister, J. Doorbar, S. Sandlofski, M. Gariglio, Characterization of beta papillomavirus E4 expression in tumours from epidermolysis verruciformis patients and in experimental models, Virology 423 (2012)
[22] H. Griffin, Y. Soneji, R. Van Baars, R. Arora, D. Jenkins, M. van de Sandt, Z. Wu, W. Quint, R. Jach, K. Okon, H. Huras, A. Singer, J. Doorbar, Stratification of HPV-induced cervical pathology using the virally encoded molecular marker E4 in combination with p16 or MCM, Mod. Pathol. 28 (2015) 977–993, https://doi.org/10.1038/modpathol.2015.52.

[23] H. Griffin, J. Doorbar, Detection of papillomavirus gene expression patterns in tissue sections, Curr. Protoc. Microbiol. 41 (2016), https://doi.org/10.1002/cpmc.

[24] P.E. Gravitt, The known unknowns of HPV natural history, J. Clin. Investig. 121 (2011) 4593–4599, https://doi.org/10.1172/JCI57149.

[25] F. Hinten, L.B. Hilbrands, K.A.P. Meeuwis, J. IntHout, W.G.V. Quint, A.J. Hoitsma, I.F.A.G. Massuger, W.J.G. Melscher, J.A. de Hullu, Reactivation of latent HPV infections after renal transplantation, Am. J. Transplant. 17 (2017) 1563–1573, https://doi.org/10.1111/ajt.14181.

[26] H.D. Strickler, R.D. Burk, M. Fazzari, K. Anastos, H. Minkoff, L.S. Massad, C. Hall, M. Bacon, A.M. Levine, D.H. Watts, M.J. Silverberg, X. Xue, N.F. Schlecht, S. Melnick, J.M. Palefsky, Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women, J. Natl. Cancer Inst. 97 (2005) 577–586, https://doi.org/10.1093/jnci/dji073.

[27] S.H. Liu, D.A. Cummings, J.M. Zenilman, P.E. Gravitt, R.M. Brotman, Characterizing the temporal dynamics of human papillomavirus DNA detectability using short-interval sampling, Cancer Epidemiol. Biomark. Prev. 23 (2014) 200–208, https://doi.org/10.1158/1055-9965.EPI-13-0666.

[28] C.A. Amella, L.A. Lofgren, A.M. Ronn, M. Nouri, M.J. Shikowitz, B.M. Steinberg, Latent infection induced with cottontail rabbit papillomavirus. A model for human papillomavirus latency, Am. J. Pathol. 144 (1994) 1167–1171.

[29] P.E. Gravitt, A.F. Bositch, M.I. Silver, M.A. Marks, K. Chang, A.E. Burke, R.P. Viscidi, A cohort effect of the sexual revolution may be masking an increase in human papillomavirus detection at menopause in the United States, J. Infect. Dis. 207 (2013) 272–280, https://doi.org/10.1093/infdis/jit660.

[30] R.L. Winer, J.P. Hughes, Q. Feng, L.F. Xi, S.K. Lee, S.F. O'Reilly, N.B. Kiviat, L.A. Koutsky, Prevalence and risk factors for oncogenic human papillomavirus infections in high-risk mid-adult women, Sex. Transm. Dis. 39 (2012) 848–856, https://doi.org/10.1097/OLQ.0b013e318264111c.

[31] M. Kalantari, A. Garcia-Carranza, C.D. Morales-Vazquez, R. Zuna, D.P. Montiel, I.E. Calleja-Macias, B. Johansson, S. Andersson, H. Bernard, Laser capture microdissection of cervical human papillomavirus infections: copy number of the virus in cancerous and normal tissue and heterogeneous DNA methylation, Virology 390 (2009) 261–267, https://doi.org/10.1016/j.virol.2009.05.006.

[32] S. Vinokurova, M. von Knebel Doeberitz, Differential methylation of the HPV 16 upstream regulatory region during epithelial differentiation and neoplastic transformation, PLoS One 6 (2011) e24451, https://doi.org/10.1371/journal.pone.0024451.

[33] S.M. Leonard, M. Pereira, S. Roberts, K. Cuschieri, G. Nuovo, R. Athavale, L. Young, R. Ganesan, C.B. Woodman, Evidence of disrupted high-risk human papillomavirus DNA in morphologically normal cervixes of older women, Sci. Rep. 6 (2016) 20847, https://doi.org/10.1038/srep20847.

[34] F. Karlsen, M. Kalantari, M. Chitemerere, B. Johansson, B. Hagmar, Modifications of human and viral deoxyribonucleic acid by formaldehyde fixation, Lab. Investig. 71 (1994) 604–611.

[35] C.E. Greer, S.L. Peterson, N.B. Kiviat, M.M. Manos, PCR amplification from paraffin-embedded tissues. Effects of fixative and fixation time, Am. J. Clin. Pathol. 95 (1991) 117–124.